In CRC, various groups have designed nanoparticles to target cancer cell surface biomarkers such as carcinoembryonic antigen (CEA) or folate receptor-α to direct the conventional chemotherapeutic treatments to the tumor. The gene discussed is CEACAM5; the disease is cancer.